Dyslipidemia News and Research

RSS

Dyslipidemia is a disruption in the amount of lipids in the blood.

Spanish researchers link job-related stress to dyslipidemia

Spanish researchers have studied how job stress affects cardiovascular health. The results, published in the 'Scandinavian Journal of Public Health', link this situation to dyslipidemia, a disorder that alters the levels of lipids and lipoproteins in the blood.

17 May 2013

Hypertensive patients may need firm dietary advice

People who have dyslipidemia or are overweight adopt healthier diets than those without, whereas patients with hypertension persist with some unhealthy eating patterns, study results show.

29 Apr 2013

NAFLD is an independent predictor of cardiovascular risk

A study presented today at the International Liver CongressTM 2013 - which evaluated the relationship between non-alcoholic fatty liver disease (NAFLD), early predictors of atherosclerosis and the 10-year Framingham risk score (FRS) - showed that NAFLD increases the risk of early atherosclerotic lesions independent of established cardiovascular (CV) risk factors.

26 Apr 2013

Obesity epidemic in the Asia Pacific region: an interview with Prof Drexel, European Society of Cardiology

The prevalence of obesity is about 20 % in Australia, 17 % in Japan, but only 3 – 4 % in China. Thus, Asia Pacific is a very heterogeneous region.

15 Apr 2013

Study projects potential impact of FDA-approved anti-obesity medications on Medicare spending

VIVUS, Inc. announced today that a new study demonstrates that effective medical treatment providing 10% to 15% weight loss could lead to significant improvements in Medicare spending by reversing or reducing significant health consequences such as type 2 diabetes, hypertension and dyslipidemia in obese or overweight patients.

25 Mar 2013

Cardiovascular disease risk in women higher than you think

In conjunction with International Women's Day, the European Cardiology Society reminds women that they may be at a greater risk for cardiovascular disease (CVD) than they think.

8 Mar 2013

Cholesterol levels seem to fluctuate significantly with turning seasons

Cholesterol levels seem to fluctuate significantly with the turning seasons, which may leave some people with borderline high cholesterol at greater cardiovascular risk during the winter months, according to research being presented at the American College of Cardiology's 62nd Annual Scientific Session.

7 Mar 2013

Otsuka receives FDA approval for ABILIFY MAINTENA to treat schizophrenia

Otsuka Pharmaceutical Co., Ltd. (Otsuka) and H. Lundbeck A/S (Lundbeck) announced the U.S. Food and Drug Administration (FDA) has approved ABILIFY MAINTENA (aripiprazole) for extended- release injectable suspension, an intramuscular (IM) depot formulation indicated for the treatment of schizophrenia.

1 Mar 2013

CT angiography uncovers cardiovascular disease risk

Computed tomography angiography can warn of the likelihood for major adverse cardiovascular events in patients suspected of having coronary artery disease in the absence of medically modifiable risk factors, research shows.

25 Feb 2013

Researchers discover miR-27b that regulates lipid levels in the blood

Researchers have identified a microRNA liver gene, miR-27b, which regulates lipid (cholesterol or fat) levels in the blood. This regulator gene controls multiple genes involved in dyslipidemia-abnormal blood cholesterol levels that can contribute to heart disease.

11 Feb 2013

Liver gene found to regulate cholesterol and fat blood levels

Researchers have identified a microRNA liver gene, miR-27b, which regulates lipid (cholesterol or fat) levels in the blood. This regulator gene controls multiple genes involved in dyslipidemia—abnormal blood cholesterol levels that can contribute to heart disease.

7 Feb 2013

Synageva announces 12-week data from sebelipase alfa Phase I/II study on LAL Deficiency

Synageva BioPharma Corp. (Synageva), a clinical stage biopharmaceutical company developing therapeutic products for rare diseases, today announced publication of the 12-week Phase I/II extension study data of sebelipase alfa in adults with lysosomal acid lipase deficiency (LAL Deficiency) in the online version and an upcoming print edition of Hepatology

5 Feb 2013

Increasing age, male sex and adiposity risk factors for metabolic syndrome in children

Metabolic syndrome is more likely to affect children who are obese than overweight or non-overweight and who have other characteristics associated with the disorder, such as high blood pressure or insulin resistance. A new comprehensive and systematic review of the medical literature on metabolic syndrome in children that probed deeper to evaluate the risk associated with gender, ethnicity, and geography was published in Metabolic Syndrome and Related Disorders, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers.

31 Jan 2013

Mitsubishi Tanabe Pharma in-licenses CETP inhibitor to Dezima Pharma

Dezima Pharma ('Dezima'), the biotechnology company developing innovative drugs in the field of dyslipidemia, announced today the in-licensing of a cholesteryl ester transfer protein (CETP) inhibitor DEZ-001 (formerly TA-8995) from Mitsubishi Tanabe Pharma Corporation (MTPC). Terms of the deal were not disclosed.

22 Jan 2013

Shoulder complaint linked to diabetes diagnosis

Study findings confirm suspicions that patients with diabetes have an increased risk for adhesive capsulitis of the shoulder.

7 Jan 2013

Toxin-induced insulin resistance combated in mice

French researchers have found that a protein-bound uremic toxin, p-cresyl sulfate, contributes to the development of insulin resistance in mice, providing a new potential therapeutic target for treating chronic kidney disease, they say.

4 Jan 2013

Study on prevalence of coronary atherosclerosis among U.S. soldiers

Among deployed U.S. service members who died of combat or unintentional injuries between 2001-2011 and underwent autopsies, the prevalence of coronary atherosclerosis was 8.5 percent, with factors associated with a higher prevalence of the disease including older age, lower educational level and prior diagnoses of dyslipidemia, hypertension, and obesity, according to a study in the December 26 issue of JAMA.

26 Dec 2012

Dyslipidaemia: an interview with Prof. Peter Kokkinos

Dyslipidemia is defined as abnormal levels of blood lipids (fats) and cholesterol. The most common dyslipidaemias are high blood cholesterol (Total Cholesterol) and triglyceride levels, high levels of low-density lipoprotein (LDL) cholesterol (‘bad’ cholesterol) and low levels of high-density lipoprotein (HDL) cholesterol (‘good’ cholesterol).

17 Dec 2012

Pfizer, Ligand announce FDA acceptance of bazedoxifene/conjugated estrogens NDA

Pfizer Inc. and Ligand Pharmaceuticals Incorporated today announced that the United States Food and Drug Administration (FDA) accepted for review a New Drug Application (NDA) for bazedoxifene/conjugated estrogens (BZA/CE), a potential new medicine for non-hysterectomized women for the treatment of moderate-to-severe vasomotor symptoms (VMS) and vulvar and vaginal atrophy (VVA) associated with menopause, as well as the prevention of postmenopausal osteoporosis.

14 Dec 2012

Ligand commences PG-free melphalan pivotal trial in multiple myeloma

Ligand Pharmaceuticals Incorporated announced today that it has initiated a pivotal trial of Captisol-enabled, propylene glycol-free (PG-free) high-dose melphalan as a conditioning treatment prior to autologous transplant for patients with multiple myeloma.

11 Dec 2012